Parathyroid carcinoma an unusual endocrine neoplasm: current review


  • Edgar A. Reyes-Velázquez Department of General Surgery, Unidad Médica de Alta Especialidad No. 25, Centro Médico Nacional del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, México



Parathyroid, Carcinoma, Endocrine, Neoplasm, Hypercalcemia


Parathyroid carcinoma is an unusual endocrine neoplasm, in practice, diagnosis and clinical approach is challenging, it could be suspected during pre-surgical approach or in the same surgical procedure, however most of the cases get the diagnosis with histopathology time after surgery, radical surgical approach is the first line treatment of choice, with bloc resection of parathyroid tumor, with the excision of ipsilateral thyroid lobe, cause is unknown, it generally arises as a sporadic disease, although familial cases have been described, most have a painless course, and the most frequent clinical manifestations are due to hypercalcemia secondary to excessive parathyroid hormone secretion by the tumor, on physical examination there is usually nothing evident, mortality is generally due to intractable hypercalcemia rather than to tumor, survival at 5 and 10 years has been reported between 70 to 100% and 50 to 90% respectively.


Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest. 2016;39:595-606.

Cetani F, Frustaci G, Torregrossa L, Magno S, Basolo F, Campomori A, et al. A nonfunctioning parathyroid carcinoma misdiagnosed as a folicular thyroid nodule. World J Surg Oncol. 2015;13:1-5.

Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679-86.

Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156-74.

Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13:11-23.

Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma: a clinical and genetic perspective. Minerva Endocrinol. 2018;43:144-55.

Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma. Front Horm Res. 2019;51:63-76.

Hahn MA, Marsh DJ. Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett. 2007;581:5070-4.

Ryhanen EM, Leijon H, Metso S, Eloranta E, Korsoff P, Ahtiainen P, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56:991-1003.

Christakis I, Vu T, Chuang HH, Fellman B, Figueroa AMS, Williams MD, et al. The diagnostic accuracy of neck ultrasound, 4D-computed tomography and sestamibi imaging in parathyroid carcinoma. Eur J Radiol. 2017;95:82-8.

Delellis RA. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma. Endocr Pathol. 2008;19:221-5.

Christakis I, Silva AM, Williams MD, Garden A, Grubbs EG, Busaidy NL, et al. Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: the MD Anderson experience of 35 years. Pract Radiat Oncol. 2017;7:e463-70.

Rozhinskaya L, Pigarova E, Sabanova E, Mamedova E, Voronkova I, Krupinova J, et al. Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol Diabetes Metab Case Rep. 2017;16-0113.

Silva-Figueroa AM, Hess KR, Williams MD, Clarke CN, Christakis I, Graham PH, et al. Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg. 2017;224:980-7.

Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P, et al. CDC73 mutational status and los of parafibromin in the outcome of parathyroid cancer. Endocr Connect. 2013;2:186-95.




How to Cite

Reyes-Velázquez, E. A. (2023). Parathyroid carcinoma an unusual endocrine neoplasm: current review. International Journal of Research in Medical Sciences, 11(10), 3917–3920.



Review Articles